Evolution of Frameless Stereotactic Radiosurgery for Intracranial Tumors

Brain metastases represent one of the most common central nervous system malignancies encountered in oncology practice. Historically, targeted focal irradiation relied on rigid, frame-based stereotactic systems requiring invasive pin fixation to the skull. While frame-based radiosurgery established high standards for spatial precision, the physical discomfort and resource-intensive setup created notable operational challenges. To improve patient comfort and clinical workflow, modern neuro-oncology programs have widely adopted frameless stereotactic radiosurgery. This non-invasive modality utilizes custom thermoplastic masks and real-time image guidance to deliver high-dose radiation directly to intracranial targets. Consequently, clinicians achieve sub-millimeter target localization without subjecting patients to invasive head frames. Although initial technical evaluations demonstrated promising accuracy, long-term clinical data evaluating oncologic durability remained limited. Recent longitudinal clinical evidence has provided critical insights into the real-world durability of single-fraction frameless delivery. Researchers evaluated long-term outcomes in a large cohort, providing strong evidence regarding tumor control, overall survival, and treatment safety. As a result, radiation oncologists can confidently integrate frameless workflows into routine practice, knowing that non-invasive immobilization maintains high therapeutic precision.

Study Cohort and Treatment Parameter Specifications

To evaluate the long-term clinical efficacy of non-invasive radiosurgery, investigators conducted a comprehensive retrospective study analyzing patients treated between 2018 and 2024. The institutional analysis evaluated 140 consecutive patients presenting with 362 distinct brain metastases. Primary malignancies reflected real-world epidemiological distributions, with non-small cell lung cancer comprising thirty-two percent of cases. Additionally, breast cancer accounted for twenty-one percent, melanoma represented sixteen percent, and gastrointestinal cancers comprised nine percent of the cohort. Clinicians delivered single-fraction treatments utilizing a median marginal dose of 20 Gy to targets with a mean volume of 0.14 cc. Furthermore, the longitudinal nature of this study provided a median clinical follow-up duration of 2.4 years. By examining a diverse spectrum of primary tumor histologies, investigators ensured that their findings accurately reflected standard oncology referrals. Moreover, target volume selection and dosimetric planning strictly adhered to standardized radiosurgical benchmarks, ensuring consistent energy delivery. Ultimately, this large cohort represents one of the most substantial single-institution frameless datasets published to date.

Efficacy of Frameless Stereotactic Radiosurgery in Local Tumor Control

The primary outcome metric for evaluating stereotactic radiosurgery remains local tumor control at the treated site. Concerns historically persisted regarding whether minor patient movement during frameless delivery could compromise steep dose fall-off gradients. However, study results revealed exceptionally high rates of local control, dispelling concerns regarding non-invasive mask stabilization. At one year following treatment, the actuarial local control rate reached an impressive ninety-eight percent. Furthermore, at two years post-treatment, local tumor control remained durable at ninety-seven percent. These high control rates indicate that advanced motion management and surface image guidance effectively preserve sub-millimeter positioning accuracy. Consequently, target lesions receive the prescribed ablative dose while adjacent critical structures remain shielded. Notably, these local control rates compare favorably with historical outcomes recorded for traditional frame-based systems. Furthermore, durable tumor stabilization was observed across all major primary tumor histologies, including radioresistant tumor types. Therefore, clinicians can assure patients that opting for frameless immobilization does not compromise local tumor control.

Overall Survival and Recurrence Dynamics

In addition to evaluating local lesion stabilization, investigators analyzed overall survival and distant brain failure dynamics within the cohort. Overall survival in patients with brain metastases depends heavily on systemic disease burden, extracranial control, and primary tumor biology. In this study, median overall survival reached 2.5 years, demonstrating favorable clinical survival outcomes within a complex patient population. Furthermore, long-term survival trends remained consistent across patients receiving targeted therapies, immunotherapy, or conventional chemotherapy alongside radiosurgery. Because radiosurgery selectively targets visible lesions while sparing uninvolved brain tissue, patients remain susceptible to developing new distant brain metastases over time. Consequently, routine surveillance neuroimaging plays a crucial role in post-treatment monitoring. When new distant intracranial metastases emerge, frameless delivery offers a distinct clinical advantage by facilitating seamless repeat radiosurgery. Patients undergo secondary or tertiary treatments without experiencing the repeated burden of invasive frame placement. Additionally, avoiding whole-brain radiation therapy preserves cognitive function and maintains health-related quality of life for long-term survivors.

Toxicity Profile and Radiation Necrosis Incidence

Safety considerations represent a vital pillar when evaluating high-dose focal radiation techniques within the central nervous system. Radiation necrosis represents one of the most serious long-term toxicities associated with stereotactic radiosurgery, potentially causing localized edema and focal neurological deficits. In this comprehensive cohort, safety outcomes were exceptionally favorable. Only one patient, representing just 0.7 percent of the cohort, developed symptomatic radiation necrosis following single-fraction treatment. Furthermore, the incidence of new-onset seizures and severe acute neurotoxicity remained extremely low throughout the extended clinical follow-up period. This remarkably low toxicity rate underscores the safety of delivering 20 Gy marginal doses using frameless motion management. By combining accurate target delineation with steep dose gradients, clinicians minimized unnecessary radiation exposure to surrounding healthy brain tissue. Consequently, patients experienced minimal treatment-related morbidity, maintaining functional independence throughout their care plan. Additionally, the low risk of radiation necrosis enables radiation oncologists to treat lesions located near sensitive eloquent cortex safely.

Integrating Frameless Workflows into Clinical Practice

The long-term evidence provided by this study reinforces the clinical role of non-invasive radiosurgery in modern neuro-oncology. Transitioning from rigid frame fixation to mask-based frameless delivery offers substantial operational and humanistic benefits. Patients experience significantly reduced pre-procedure anxiety, eliminated pin-site pain, and lower risks of localized infection. Simultaneously, clinical teams benefit from streamlined treatment scheduling, improved machine throughput, and greater flexibility during multi-target planning sessions. To maximize clinical success with frameless delivery, institutional teams must establish rigorous quality assurance protocols, including daily surface imaging calibrations and real-time motion tracking. Furthermore, radiation oncologists, neurosurgeons, and medical physicists must collaborate closely during target contouring and treatment plan verification. As systemic cancer therapies continue to prolong patient survival, maintaining excellent intracranial control without treatment toxicity becomes increasingly paramount. Non-invasive stereotactic radiosurgery meets this demand by delivering precise, safe, and durable local tumor control.

Frequently Asked Questions

How does frameless stereotactic radiosurgery compare to traditional frame-based treatments?

Frameless stereotactic radiosurgery utilizes thermoplastic masks and real-time surface imaging rather than invasive head frames attached with skull pins. Studies demonstrate that frameless delivery provides equivalent local tumor control and positional accuracy while dramatically improving patient comfort, reducing procedure anxiety, and streamlining clinical workflows during multi-target radiosurgery procedures.

What are the typical local control rates for frameless radiosurgery in brain metastases?

Recent long-term clinical data show excellent local tumor control rates following single-fraction frameless radiosurgery. Research demonstrates local control rates of ninety-eight percent at one year and ninety-seven percent at two years post-treatment, confirming that mask-based immobilization maintains high precision without compromising long-term oncologic efficacy.

What is the risk of radiation necrosis with single-fraction frameless delivery?

The risk of symptomatic radiation necrosis following single-fraction frameless stereotactic radiosurgery is exceptionally low. In large clinical cohorts, symptomatic radiation necrosis occurred in less than one percent of patients. Steep dose fall-off gradients and accurate real-time motion tracking protect surrounding healthy brain tissue from excessive radiation exposure.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition or treatment options. Refer to the latest local and national guidelines for clinical practice.

References

1. Kinger S et al. Frameless stereotactic radiosurgery in the management of brain metastases: long-term oncologic and toxicity outcomes. J Neurooncol. 2026 Jul 21. doi: 10.1007/s11060-026-05721-1. PMID: 42479234.


2. Habibi MA et al. Frameless stereotactic radiosurgery for brain metastasis: a systematic review and meta-analysis. Neurosurg Rev. 2024 Aug 13;47(1):423. doi: 10.1007/s10143-024-02666-9.


3. Pham NLL et al. Frameless, real-time, surface imaging-guided radiosurgery: update on clinical outcomes for brain metastases. Transl Cancer Res. 2014;3(4):351-357.